Ann: Positive clinical trial results for cancer vaccine, page-8

I think it's great news. Immuno-oncology is a hot area., the same field as VLA-ASX was in. RGSH4K's pre-cliincal studies with an anti-pd11 inhibitor in could make this a genuine area of development and spark partnering interest. RGH4K was a challenging phase-1 trial to do. RGS has now successfully completed two phase 1 trials in separate areas, both of which were previously backed up by animals trial in both areas. This the work of a genuine biotech, preparing the ground for several value inflections points.